VIBRAINT
Brain-controlled rehabilitation robot transforming thoughts into motions for paralyzed individuals.
Website: https://vibraint.ai/
Cover Block
PUBLIC
| Name | VIBRAINT |
| Tagline | Brain-controlled rehabilitation robot transforming thoughts into motions for paralyzed individuals. |
| Headquarters | Richmond Hill, Canada |
| Founded | 2017 |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Robotics |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
Links
PUBLIC
- Website: https://vibraint.ai/
- LinkedIn: https://ca.linkedin.com/showcase/vibraint
- Facebook: https://www.facebook.com/vibraintAI/
Executive Summary
PUBLIC VIBRAINT is developing a brain-controlled rehabilitation robot that aims to translate thought into motion for patients with severe paralysis, a technical frontier in neurotechnology that could unlock new treatment pathways for a large, underserved patient population [vibraint.ai, retrieved 2024]. Founded in 2017 by serial entrepreneur Ilia Borishchev, the company has focused its efforts on the VIBRAINT RehUp system, which integrates a non-invasive brain-computer interface, robotics, and virtual reality to facilitate upper limb rehabilitation, particularly after stroke or spinal cord injury [vibraint.ai, retrieved 2024] [LinkedIn, retrieved 2026]. The product's stated emphasis on affordability and suitability for early, at-home use attempts to address two significant barriers in conventional neurorehabilitation: high cost and limited access to clinical facilities [h2i.utoronto.ca, retrieved 2024].
Borishchev brings a multi-decade track record in building high-tech ventures, which he has applied to this project as a "lifetime" commitment, though the public record does not detail specific prior experience in medical device development or regulatory affairs [vibraint.ai, retrieved 2024]. The company's capitalization is not publicly disclosed, but it has gained validation through participation in Canadian accelerators including ventureLAB and the University of Toronto's Health Innovation Hub, suggesting support within the local ecosystem [ventureLAB, retrieved 2024] [h2i.utoronto.ca, retrieved 2024]. Over the next 12-18 months, the key milestones for investors to monitor will be the transition from accelerator support to a disclosed funding round, the generation of initial clinical validation data, and the articulation of a clear regulatory pathway for a Class II medical device in North America.
Data Accuracy: YELLOW -- Core product claims are sourced from company materials; accelerator participation is confirmed. Funding, revenue, and detailed team composition lack independent corroboration.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Robotics |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
Company Overview
PUBLIC
The company's origin story is one of personal focus following a geographic and professional shift. Founder Ilia Borishchev, described as a serial high-tech entrepreneur with a 30-year track record, relocated to Canada in 2016 and subsequently founded VIBRAINT Inc. in 2017 [vibraint.ai, retrieved 2024] [LinkedIn, retrieved 2026]. The VIBRAINT RehUp project is framed as his "lifetime project," a pivot into neurotech and medtech that leverages his experience in building ventures and teams [vibraint.ai, retrieved 2024] [LinkedIn, retrieved 2026].
Headquartered in Richmond Hill, Ontario, the company's public development timeline is marked by participation in Canadian academic and government-backed accelerators rather than traditional funding announcements. It was a nominee in the 2021 Ideation Challenge, a Judges Prize winner that same year, and an awardee from 2022 through 2024 [vibraint.ai, retrieved 2024]. In 2024, VIBRAINT was also named a Pitch-Off winner [vibraint.ai, retrieved 2024]. The company has been associated with ventureLAB, the University of Toronto's Health Innovation Hub (H2i), and the Access to Success Organization, which indicates a sustained engagement with the regional innovation ecosystem for validation and support [ventureLAB, retrieved 2024] [h2i.utoronto.ca, retrieved 2024].
A clinical advisor, Igor Lavrov, is listed in relation to the company, suggesting early efforts to build medical and research credibility for its rehabilitation device [ZoomInfo, retrieved 2026]. The legal entity appears to be VIBRAINT Inc., incorporated in Canada, though specific registration details are not part of the public narrative.
Data Accuracy: YELLOW -- Key founding and milestone claims are sourced from the company's own website and founder's LinkedIn, with accelerator participation corroborated by third-party program pages. No independent business registry or major media coverage was found to verify the corporate timeline.
Product and Technology
MIXED
The company's singular focus is the VIBRAINT RehUp, a hardware-software system designed to translate conscious intent into physical motion for patients with upper-limb paralysis. The device is presented as an integrated platform combining a non-invasive brain-computer interface (BCI), a robotic actuator, and a virtual reality (VR) environment, all orchestrated by artificial intelligence [vibraint.ai, retrieved 2024]. The core proposition is to enable rehabilitation exercises where a patient's intention to move a paralyzed arm is detected by the BCI, executed by the robot, and visually reinforced within a VR simulation, creating a closed-loop feedback system intended to promote neural recovery [vibraint.ai, retrieved 2024].
Product positioning emphasizes accessibility and early intervention. The system is described as affordable and easy to use, with a design goal of facilitating at-home rehabilitation shortly after a stroke or spinal cord injury [h2i.utoronto.ca, retrieved 2024]. The target clinical setting is neurology and rehabilitation departments within hospitals, clinics, and specialized centers, with end users identified as clinicians, researchers, and the patients and families affected by motor impairments [en.istok-audio.com, retrieved 2026] [ZoomInfo, retrieved 2026]. Specific clinical claims include reducing motor deficit in patients with severe to moderate upper-limb paralysis due to strokes or other central nervous system injuries [en.istok-audio.com, retrieved 2026].
Data Accuracy: YELLOW -- Product claims are sourced primarily from the company's own website and affiliated accelerator pages; independent technical validation or detailed specification sheets are not publicly available.
Market Research
PUBLIC The market for neurorehabilitation technology is expanding, driven by a growing patient population with limited treatment options and a shift toward home-based care. VIBRAINT's target segment sits at the intersection of several established and emerging healthcare markets, including stroke rehabilitation, spinal cord injury care, and the broader brain-computer interface (BCI) sector.
Demand is anchored by a significant and persistent clinical need. The company cites global statistics of 120 million people living immobilized and 500,000 annual spinal cord injuries leading to paralysis [vibraint.ai, retrieved 2024]. Stroke is a primary driver, with the company noting one in six people will experience one [vibraint.ai, retrieved 2024]. Conventional rehabilitation often offers limited aid for severe paralysis, creating a gap for assistive technologies that can enable earlier and more intensive therapy [vibraint.ai, retrieved 2024]. A tailwind comes from the healthcare system's push toward cost-effective, decentralized care; VIBRAINT explicitly positions its RehUp device for early and at-home rehabilitation [h2i.utoronto.ca, retrieved 2024], which aligns with broader trends in telehealth and remote patient monitoring.
Adjacent and substitute markets provide context for the commercial landscape. The core substitute remains traditional physical and occupational therapy, a multi-billion dollar global industry. The adjacent market of medical robotics for rehabilitation was valued at approximately $1.3 billion in 2023 and is projected to grow at a compound annual rate near 14% through 2030, according to a third-party analyst report (analogous market, Grand View Research) [Grand View Research, 2024]. The non-invasive BCI market, a key enabling technology for VIBRAINT, is a smaller but faster-growing segment. One public report estimates the global medical brain-computer interface market size at $1.5 billion in 2022, forecast to expand at over 17% CAGR through 2030 (analogous market, Precedence Research) [Precedence Research, 2023].
Regulatory pathways and reimbursement models are critical macro forces. As a Class II medical device in jurisdictions like Canada and the United States, the VIBRAINT RehUp system would require clearance from Health Canada and the U.S. Food and Drug Administration (FDA) for commercial sale. This process is a significant gating factor for revenue. Success also hinges on securing reimbursement codes from public and private insurers, which is often a longer-term commercial challenge than achieving regulatory approval. The company's focus on affordability suggests a strategy to ease adoption, but the specifics of its regulatory status and reimbursement planning are not public.
Global Medical BCI Market (2022) | 1.5 | $B
Rehabilitation Robotics Market (2023) | 1.3 | $B
The available sizing data, while from analogous markets, indicates VIBRAINT is operating in niches with strong growth tailwinds. The high projected growth rates for both rehabilitation robotics and medical BCIs suggest investor interest and clinical openness to technological solutions. However, the company's specific serviceable obtainable market (SOM) is not quantified, and its ability to capture share will depend on clinical validation, pricing, and sales execution within hospital neurology and rehabilitation departments [en.istok-audio.com, retrieved 2026].
Data Accuracy: YELLOW -- Market size figures are from third-party reports for analogous sectors, not VIBRAINT's specific product segment. Patient statistics are sourced from the company's website. Regulatory and reimbursement analysis is inferred from standard medical device pathways.
Competitive Landscape
MIXED VIBRAINT operates in a niche defined by the convergence of non-invasive brain-computer interfaces (BCI), robotics, and virtual reality for motor rehabilitation, a segment where its primary competition comes from large medical device incumbents, specialized neurotech startups, and adjacent therapeutic substitutes.
Given the limited public data on direct, named competitors, a detailed comparison table is not feasible. A competitive analysis must therefore rely on mapping the broader category of neurorehabilitation devices.
- Incumbent medical device giants. Companies like Hocoma (a DIH International company) and Tyromotion dominate the clinical rehabilitation robotics market with sophisticated, FDA-cleared exoskeletons and end-effector robots [PitchBook, 2024]. Their products, such as the ArmeoSpring, are well-established in hospital physiotherapy departments but are typically high-cost, stationary systems focused on assisted movement rather than direct brain-signal control.
- Specialized neurotech challengers. A newer wave of startups, including Neurable (focused on non-invasive BCI for cognitive assessment and control) and MindMaze (combining VR and motion capture for neurorehabilitation), are exploring similar technological intersections [Crunchbase, 2025]. Their approaches, however, often prioritize different clinical applications or user interfaces, such as gamified cognitive therapy rather than physical limb actuation.
- Adjacent therapeutic substitutes. The competitive set extends to non-robotic alternatives. These include traditional occupational therapy, functional electrical stimulation (FES) devices like the Bioness H200, and emerging telehealth platforms that guide patients through prescribed movements without robotic assistance. These substitutes compete on cost and accessibility rather than technological novelty.
VIBRAINT's defensible edge today appears to rest on its specific integration of a non-invasive BCI with a robotic actuator for the upper limbs, targeting the early post-stroke and spinal cord injury window for at-home use. This combination of affordability and home deployment, as claimed by the company, is a point of differentiation from large, clinic-bound robotic systems [h2i.utoronto.ca, 2024]. However, this edge is perishable; it depends on maintaining a technological lead in BCI signal processing and keeping hardware costs low, both areas where well-funded competitors could rapidly advance. The company's participation in Canadian accelerators like ventureLAB and H2i provides a network and validation advantage within that ecosystem, but it does not constitute a commercial moat [ventureLAB, 2024].
The company is most exposed in two key areas. First, it lacks the established clinical validation and regulatory clearance that incumbents possess, which are critical for sales into neurology departments and reimbursement from insurers. Second, its focus on upper-limb paralysis for stroke and spinal cord injury places it in direct competition with subsidized or in-kind donation programs from larger manufacturers, which can use scale to lower effective price points for institutions. A specific named risk is the potential for a company like Neurable or a subsidiary of a larger player like Abbott Neuromodulation to develop a similar integrated system, leveraging their existing distribution channels and clinical research budgets to outpace VIBRAINT's commercialization.
The most plausible 18-month competitive scenario hinges on clinical proof and initial deployments. If VIBRAINT can secure a pivotal clinical study result demonstrating superior motor recovery rates compared to conventional therapy, it could attract partnership interest from a regional hospital network or a mid-tier medical device distributor, becoming a "winner" in the niche of early-intervention, home-based neuro-robotics. Conversely, if a competitor like MindMaze or a new entrant with deeper funding launches a directly comparable at-home BCI-robotic system within that timeframe, VIBRAINT could become a "loser," relegated to a smaller geographic market or forced into a technology licensing model rather than a direct sales play. The outcome will likely be determined less by pure technological superiority and more by the speed and capital efficiency of achieving regulatory milestones and initial commercial traction.
Data Accuracy: YELLOW -- Competitive mapping is inferred from category analysis; direct competitor details are not publicly available.
Opportunity
PUBLIC The prize for VIBRAINT is a fundamental shift in the economics and outcomes of post-stroke and spinal cord injury rehabilitation, moving a multi-billion dollar global market from passive care to active, data-driven recovery at home.
The headline opportunity is for VIBRAINT RehUp to become the default first-line therapeutic device for upper-limb motor rehabilitation in major healthcare systems. This outcome is reachable not because of speculative technology but because the company's stated wedge,affordability and home use,directly attacks the two largest bottlenecks in neurological care: cost and access. Conventional rehabilitation for severe paralysis offers limited help, as the company notes, and is often confined to clinical settings [vibraint.ai, retrieved 2024]. By combining a non-invasive brain-computer interface with robotics and VR into a single, purportedly easy-to-use system, VIBRAINT is positioning its product for early and at-home intervention [h2i.utoronto.ca, retrieved 2024]. If the clinical efficacy matches the technical premise, the device could transition from a specialized tool in hospital neurology departments to a standard piece of durable medical equipment prescribed for home recovery, capturing recurring revenue from both institutional sales and ongoing patient subscriptions or consumables.
Growth from a novel prototype to standard of care would likely follow one of several concrete paths. The scenarios below outline plausible, citation-backed routes to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Clinical Pathway Adoption | VIBRAINT RehUp is incorporated into national or private insurer reimbursement codes for post-stroke rehabilitation. | Publication of a positive clinical trial result from a partner research hospital, leading to a Health Technology Assessment (HTA) review. | The company's focus on hospitals and clinics as target clients suggests engagement with clinical research pathways [en.istok-audio.com, retrieved 2026]. Accelerator support from the University of Toronto's Health Innovation Hub (H2i) provides a natural conduit for academic validation [h2i.utoronto.ca, retrieved 2024]. |
| Home-Use Market Creation | The device is prescribed directly to patients for long-term, maintenance therapy, creating a high-margin recurring revenue stream. | A partnership with a major home healthcare equipment distributor or a national physiotherapy association. | The product claim emphasizes affordability and ease of use for at-home rehabilitation, explicitly targeting patients and families [h2i.utoronto.ca, retrieved 2024] [ZoomInfo, retrieved 2026]. This positions it for a direct-to-consumer (via prescription) model, which bypasses some institutional sales friction. |
Compounding for VIBRAINT would manifest as a data-driven therapeutic flywheel. Each clinical deployment and home-use session generates proprietary data on brain signal patterns correlated with motor recovery. This dataset, unique to the company's BCI and robotic system, could be used to continuously refine the AI algorithms that translate intention into motion, improving therapeutic outcomes over time [vibraint.ai, retrieved 2024]. Better outcomes would drive higher clinician recommendation rates and stronger payer justification, fueling further adoption and generating even more data. This creates a potential data moat: efficacy becomes tied to the proprietary training data collected from the installed base, making it difficult for a new entrant without a comparable deployment footprint to match performance.
The size of the win can be framed by the addressable population. The company cites a global population of 120 million people living immobilized [vibraint.ai, retrieved 2024]. Even capturing a single-digit percentage of the annual new cases of stroke (1 in 6 people) and spinal cord injury (500,000 paralyzed annually) represents a multi-billion dollar addressable market for a capital equipment device [vibraint.ai, retrieved 2024]. While no direct public comparable exists for a brain-controlled home rehabilitation robot, the valuation of companies in adjacent neurotech and robotic surgery spaces (e.g., Zimmer Biomet's acquisition of Medtech for robotic neurosurgery) suggests that a category-defining platform in a large, underserved medical market can command significant premiums. If the Clinical Pathway Adoption scenario plays out, VIBRAINT could scale to a valuation anchored to the lifetime cost savings it provides healthcare systems, a scenario that supports a venture-scale outcome.
Data Accuracy: YELLOW -- Core product claims and target market sizing are from the company's own materials and affiliated accelerator pages; clinical and commercial traction to support growth scenarios is not publicly cited.
Sources
PUBLIC
[vibraint.ai, retrieved 2024] Vibraint | Groundbreaking Brain-controlled Rehabilitation - Experience the future of rehabilitation with VIBRAINT RehUp | https://vibraint.ai/
[LinkedIn, retrieved 2026] Ilia Borishchev - VIBRAINT Inc. | https://www.linkedin.com/in/iliaborishchev/
[h2i.utoronto.ca, retrieved 2024] Health Innovation Hub (H2i) @ U of T | VIBRAINT - Health Innovation Hub (H2i) @ U of T | https://h2i.utoronto.ca/startup/vibraint/
[ventureLAB, retrieved 2024] Vibraint AI | ventureLAB | https://www.venturelab.ca/portfolio/vibraint-ai
[en.istok-audio.com, retrieved 2026] APC VIBRAINT RehUp | https://www.en.istok-audio.com/products/rehabilitation/apc-vibraint-rehup/
[ZoomInfo, retrieved 2026] Contact Igor Lavrov, Email: ****@vibraint.ai & Phone Number | Clinical Advisor at Vibraint - ZoomInfo | https://www.zoominfo.com/p/Igor-Lavrov/-1512236577
[Grand View Research, 2024] Rehabilitation Robotics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/rehabilitation-robotics-market
[Precedence Research, 2023] Medical Brain Computer Interface Market Size, Growth, Report 2023-2032 | https://www.precedenceresearch.com/medical-brain-computer-interface-market
[PitchBook, 2024] Hocoma AG Company Profile | https://pitchbook.com/profiles/company/22986-17
[Crunchbase, 2025] Neurable Company Profile | https://www.crunchbase.com/organization/neurable
Articles about VIBRAINT
- VIBRAINT's Brain-Controlled Robot Wires a Thought Into a Motion — The Canadian startup's non-invasive RehUp system is a bet on early, at-home rehabilitation for stroke survivors.